Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study
In this RWS, SG demonstrated effectiveness and safety in patients with previously treated metastatic TNBC, consistent with ASCENT trial outcomes. Further research is needed to explore the efficacy of SG in different patient populations and healthcare systems.
Authors
- Renata Pacholczak‐Madej (ORCID: https://orcid.org/0000-0002-6535-4841)
- Joanna Streb (ORCID: https://orcid.org/0000-0003-2147-7177)
- Michał Jarząb (ORCID: https://orcid.org/0000-0002-2642-9724)
- Marek Ziobro (ORCID: https://orcid.org/0000-0002-6870-9492)
- Małgorzata Pieniążek (ORCID: https://orcid.org/0000-0001-5864-0877)
- Aleksandra Łacko
- Manuela Las‐Jankowska (ORCID: https://orcid.org/0000-0002-3970-0368)
- Anna Polakiewicz-Gilowska (ORCID: https://orcid.org/0000-0002-2175-7067)
- Mirosława Püsküllüoğlu (ORCID: https://orcid.org/0000-0002-2647-9625)
- Aleksandra Grela-Wojewoda (ORCID: https://orcid.org/0000-0002-6727-8926)
- Agnieszka Rudzińska (ORCID: https://orcid.org/0009-0005-7243-4689)
- Paulina Kilian-Van Miegem
Institutions
- Jagiellonian University (PL)
- Bydgoszcz University of Science and Technology (PL)
- Nicolaus Copernicus University (PL)
- Wroclaw Medical University (PL)
- University of Bydgoszcz (PL)
- Greater Poland Cancer Center (PL)
- National Institute of Oncology (HU)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Grochowski Hospital (PL)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1007/s40487-024-00307-1
- Citations
- 10
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.54